Core Insights - Elicio Therapeutics announced preliminary data from the AMPLIFY-7P Phase 1a study of its investigational cancer vaccine ELI-002 7P, showing it was well tolerated and correlated with tumor biomarker reduction [1][4][6] Study Overview - The AMPLIFY-7P study evaluates ELI-002 7P in patients with mKRAS-driven solid tumors that are positive for minimal residual disease after standard treatment [2][10] - ELI-002 7P utilizes Elicio's proprietary Amphiphile technology to stimulate immune responses against seven KRAS mutations, which are responsible for 25% of all solid tumors [2][9] Preliminary Results - ELI-002 7P generated a ~100x mKRAS-specific T cell response compared to baseline levels, with 100% of patients showing mKRAS-specific T cell responses [6][7] - At the recommended Phase 2 dose of 4.9 mg, tumor biomarker reductions were observed in 71% of evaluable patients [6][7] - Antigen-spreading was noted, with increased T cell responses targeting non-immunizing personalized tumor neoantigens in 100% of evaluable patients at the 4.9 mg dose level [6][13] Expert Commentary - Experts expressed encouragement regarding the favorable safety profile and early antitumor effects of ELI-002 7P, highlighting its potential to provide broader coverage for patients with KRAS mutations [3][4] Presentation Details - The findings will be presented at the ASCO Annual Meeting on June 1, 2024, with the abstract titled "AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine" [5]
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting